Qiagen Overview

  • Founded
  • 1984

Founded
  • Status
  • Public

  • Employees
  • 6,200

Employees
  • Stock Symbol
  • QGEN

Stock Symbol
  • Investments
  • 59

  • Share Price
  • $49.39

  • (As of Thursday Closing)

Qiagen General Information

Description

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (45% of 2021 sales), followed by EMEA (36%) and Asia-Pacific (19%).

Contact Information

Website
www.qiagen.com
Formerly Known As
Diagen
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Stock Exchange
NYS
Primary Office
  • Qiagen Strasse 1
  • 40724 Hilden
  • Germany
+49 02103 000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Qiagen Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$49.39 $49.44 $40.38 - $51.30 $11.3B 228M 754K $2.04

Qiagen Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 10,023,767 13,618,310 13,375,487 8,720,977
Revenue 2,225,932 2,251,657 1,870,346 1,526,424
EBITDA 813,831 885,686 705,771 205,754
Net Income 463,553 512,599 359,188 (41,455)
Total Assets 6,516,617 6,146,954 5,869,619 5,235,616
Total Debt 2,289,246 1,963,818 1,946,199 1,725,091
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Qiagen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Qiagen‘s full profile, request access.

Request a free trial

Qiagen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins.
Biotechnology
Hilden, Germany
6,200 As of 2022
00000
000000&0

000000

te irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
000000000 00000 (000
Madison, WI
0000 As of 0000
000000000000

000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000000000 000000000
San Diego, CA
00000 As of 0000
00000
0000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Qiagen Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Promega Formerly PE-Backed Madison, WI 0000 000000000000
00000000 Formerly VC-backed San Diego, CA 00000 00000 0000000000 00000
You’re viewing 2 of 2 competitors. Get the full list »

Qiagen Patents

Qiagen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4123653-A1 Method of evaluating a mutational burden Pending 22-Jul-2021 000000000 0
EP-4099332-A1 Method for reviewing and manipulating of digital pcr data Pending 01-Jun-2021 000000000 0
US-20220162689-A1 Method and device for sequencing and detecting dna/rna directly on a sensor Pending 23-Nov-2020 0000000000 0
EP-3971302-A1 Method for detecting 5-hydroxymethylated cytosine Pending 16-Sep-2020 0000000000
US-20220073976-A1 Cyclone rolling circle amplification, double primer for rolony and repli-rolony and pair-end sequencing process Pending 10-Sep-2020 C12Q1/6806
To view Qiagen’s complete patent history, request access »

Qiagen Executive Team (54)

Name Title Board Seat Contact Info
Thierry Bernard Chief Executive Officer, Managing Director & Member of the Executive Committee
Peer Schatz Senior Advisor
Roland Sackers Chief Financial Officer & Managing Director
Masae Kawamura Senior Director, Medical and Scientific Affairs
Alexandra Koenig Investor Relations Coordinator
You’re viewing 5 of 54 executive team members. Get the full list »

Qiagen Board Members (7)

Name Representing Role Since
Elizabeth Tallett Self Board Member 000 0000
Jonathan Sheldon Ph.D Qiagen Senior Vice President, QIAGEN Digital Insights & Member of the Executive Committee 000 0000
Lawrence Rosen Qiagen Chairman of the Supervisory Board & Supervisory Director 000 0000
Metin Colpan Qiagen Co-Founder & Supervisory Director 000 0000
Thomas Ebeling Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Qiagen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Qiagen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Qiagen‘s full profile, request access.

Request a free trial

Qiagen Investments & Acquisitions (59)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 09-Jan-2023 0000000000 00000 Other Commercial Products 0000000 0
00000 26-Apr-2022 0000000000 Biotechnology 000000 00
0000000 00000 19-Jan-2022 00000 0000 Biotechnology
0000000 00000 17-Sep-2020 0000000000 00000 Other Healthcare Technology Systems 0000 0000
Formulatrix (Digital PCR) 31-Jan-2019 Corporate Asset Purchase 00000 Buildings and Property 0000 0000
You’re viewing 5 of 59 investments and acquisitions. Get the full list »

Qiagen Subsidiaries (3)

Company Name Industry Location Founded
Verogen Other Commercial Products San Diego, CA 2017
0000000 000000000 Other Healthcare Technology Systems Ann Arbor, MI 0000
0000000000 Biotechnology Beverly, MA 0000
To view Qiagen’s complete subsidiaries history, request access »

Qiagen ESG

Risk Overview

Risk Rating

Updated January, 31, 2023

15.43 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

0.00

Percentile

Laboratory Equipment and Services

Subindustry

00 of 70

Rank

00.00

Percentile

To view Qiagen’s complete esg history, request access »

Qiagen Exits (13)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 07-Jan-2019 00000 00000 00 000.00 Completed
  • 000000
00000000 20-Mar-2018 00000 00000 00 000.00 Completed
  • 5 buyers
0000000 0000000000 07-Jan-2016 00000 00000 00 0000 Completed
  • 7 buyers
0000000 0000000000 04-Sep-2015 00000 0000000 Completed
  • 2 buyers
Curetis 24-Nov-2014 Later Stage VC 000.00 Completed
  • 10 buyers
You’re viewing 5 of 13 exits. Get the full list »